

## WP2 - Schedule of Follow-up assessments

	COVID-19 (2 weeks <sup>1</sup> ± 2 weeks)	3 months <sup>1</sup> ± 1 month	6 months <sup>1</sup> ± 1 month	12 months <sup>1</sup> ± 1 month	18 months <sup>1</sup> ± 1 month
<b>Screening/baseline</b>					
Demographics <sup>2</sup>					
Healthcare setting <sup>3</sup>					
Length of hospital stay, days					
ICU admission					
Medical history <sup>4</sup>					
<b>Treatment</b>					
Comorbidity management <sup>5</sup>	X	X	X	X	X
Anti-COVID therapy <sup>6</sup>	X				
Antibiotic therapy <sup>7</sup>					
Oxygen therapy <sup>8</sup>	X	X*	X*	X*	X*
SARS-CoV-2 vaccination <sup>9</sup>	X	X	X	X	X
<b>Clinical assessment</b>					
Relevant medical new events <sup>10</sup>	X	X	X	X	X
COVID-19 symptom <sup>11</sup> onset	X				
COVID-19 symptom end	X	X*	X*	X*	X*
COVID severity <sup>12</sup>	X				
SOFA score	X				
Vital signs <sup>13</sup>	X	X	X	X	X
Physical examination <sup>14</sup>	X	X	X	X	X
12-lead electrocardiography	X	X	X	X	X
6-minute walking test	X	X	X	X	X
DLCO (diffusing capacity for carbon monoxide)	X	X	X	X	X
Pulmonary function test <sup>15</sup>	X	X	X	X	X
<b>Questionnaires</b>					
Functional status <sup>16</sup>	X	X	X	X	X
Respiratory impairment <sup>17</sup>	X	X	X	X	X
Mental health <sup>18</sup>	X	X	X	X	X
Perceived risk of re-infection/admission/re-admission <sup>19</sup>	X	X	X	X	X
Adherence to main preventative non-pharmacological measures <sup>20</sup>	X	X	X	X	X
SARS-CoV-2 vaccination: acceptance/non-acceptance and reasons <sup>21</sup>	X	X	X	X	X

<b>Imaging</b>					
Lung ultrasound	X	X	X*	X	X*
X-ray	X	X	X*	X*	X*
High-resolution CT scan	X	X	X*	X*	X*
Cardiac ultrasound	X	X	X*	X	X*
Cardiac MRI <sup>22</sup>	X <sup>21</sup>	X <sup>21</sup>	X*	X <sup>21</sup>	X*
<b>Biochemistry</b>					
Blood tests <sup>23</sup>	X	X	X*	X	X*
Arterial blood gas test (pO2/pCO2/pH)	X	X	X*	X*	X*
Urine tests <sup>24</sup>	X	X	X*	X	X*
<b>Immunology</b>					
Immune - serology and type I IFNs autoantibodies	X	X	X	X	X
Immune - cytokine and chemokine	X	X <sup>35</sup>	X <sup>35</sup>	X <sup>35</sup>	X*
Immune - cellular	X	X <sup>35</sup>	X <sup>35</sup>	X <sup>35</sup>	X*
<b>Microbiological tests-NP swabs</b>					
Viral variant and metagenomics sequencing	X	X*, <sup>34</sup>	X*, <sup>34</sup>	X*, <sup>34</sup>	X*
<b>EDTA whole blood</b>					
Genetic and epigenetic analysis	X	X	X	X	X
<b>Stool Sample (faeces or rectal swab)</b>					
Metagenomic sequencing	X		X		X
<b>Adjunctive variables for specific fragile populations</b>					
<b>HIV</b>					
HIV-infection status <sup>25</sup>	X	X	X	X	X
HIV-Infection therapy <sup>26</sup>	X	X	X	X	X
Assessment of adherence to follow-up visits and antiretroviral therapy	X	X	X	X	X
<b>Elderly</b>					
Cognitive status <sup>27</sup>	X	X	X	X	X
<b>Pregnant women/new mother</b>					
History of positive SARS-CoV-2 molecular test on amniotic fluid or breast milk <sup>28</sup>					
History of detection of microthrombotic disease on placenta tissue or umbelical cord tissue					
<b>Children</b>					
History of positive SARS-CoV-2 molecular test on amniotic fluid or breast milk <sup>28</sup>					
Biometric parameters <sup>29</sup>	X	X	X	X	X

<b>Transplant</b>					
Transplant general information <sup>30</sup>					
Graft function <sup>31</sup>	X	X	X	X	X
Immunosuppressive regimen <sup>32</sup>	X	X	X	X	X
<b>Onco-haematology</b>					
Assessment of adherence to oncologic follow-up visits and therapy	X	X	X	X	X
Assessment of progression of the disease and relapse	X	X	X	X	X
Assessment of adverse events <sup>33</sup>	X	X	X	X	X

## Footnotes

Modular data capture according to level of commitment (level I, level II, level III).

Level I	Assessments in level I are mandatory
Level II	Customized according to the feasibility of each cohort

\*Reassessed only if outside the normal ranges at the previous assessment or if clinically indicated

- Day 0: first positive SARS-CoV-2 test
- Demographics: age (years), sex, ethnic group (African, Asian, European, Latin America...), education (no formal education, lower than college, college or higher), cigarette smoking (never-smoker, former smoker, current smoker), usual residence (home, long-term care facility, public dormitory, prison, homeless), current occupation (student, unemployed with no benefits, unemployed with benefits, employed, self-employed, informal worker)
- Healthcare setting: (a) outpatient (b) non-intensive care unit (c) intensive care unit.
- Medical history: cardiovascular diseases (hypertension, coronary artery disease, congestive heart failure), diabetes (without insulin, with insulin), chronic respiratory disease (asthma, chronic obstructive pulmonary disease, obstructive sleep apnea, restrictive lung disease, pulmonary hyper-tension), kidney disease (chronic with/without dialysis), liver disease other than cancer (HBV/HCV/HDV chronic viral hepatitis, other chronic disease, cirrhosis), metabolic disease, immunosuppressive conditions (solid organ transplant recipient, autoimmune diseases), cancer (solid cancer, hematological malignancies, type of primitive cancer/hematological malignancies, presence of metastases, if ongoing chemotherapy), mental or neurological disorders (psychiatric illness, anxiety disorder, mood disorder, psychotic disorder, Alzheimer disease, dementia other than Alzheimer, Parkinson's disease, myasthenia gravis, epilepsy, stroke (with/without residual deficits, neuromuscular disease, multiple sclerosis), muscular dystrophy, amyotrophic lateral sclerosis); TB co-infection; other opportunistic co-infection (specify) for HIV population
- Comorbidity management: drug name and dose (to include only treatments taken regularly)
- Anti-COVID therapy: drug name, maintenance dose, and duration
- Antibiotic therapy: drug name, dose, duration, and type of treated infection
- Oxygen therapy: nasal prongs, face mask, face mask with reservoir, high-flow nasal cannula, non-invasive ventilation, mechanical ventilation; numbers of O<sub>2</sub> (L/min) provided (maximum reached) and fraction of inspired O<sub>2</sub> (FiO<sub>2</sub>) provided (maximum reached)
- SARS-CoV-2 vaccination: vaccine name, date of administration
- Relevant new medical events or worsening of previous conditions, including deep venous thrombosis, pulmonary embolism, infections (including a new SARS-CoV-2-infection during follow-up), malignancies (type of cancer, overall stage).

11. Symptoms: abdominal pain, ageusia/dysgeusia, anosmia, balance impairment, behavior disorder, chest pain or chest tightness, confusion, cough, delirium, diarrhea, disrupted sleep, dizziness, dyspnea, fatigue, fever (including low-grade fever), headache, hypothermia, impaired cognitive status, lethargy, loss of appetite, mood affective disorder, myalgia, nausea/vomiting, palpitation, phlegm, runny nose, sore throat, stuffed nose, syncope, wheeze.
12. WHO Clinical Progression Scale
13. Vital signs: dead/alive, blood pressure, body temperature, heart rate, respiratory rate, peripheral oxygen saturation
14. Physical examination: BMI, abdominal examination, pulmonary examination, cardiac examination, neurological examination, peripheral vascular examination
15. Pulmonary function test: FEV1, FVC, FEV1/FVC, TLC, FRC, RV
16. Questionnaires to address the functional status: Post-COVID-19 Functional Status (PCFS) Scale, Global Physical Activity, Questionnaire (GPAQ), Barthel Index, Medical Outcome Study Short , Form (MOS SF)-36 Score, EuroQol five-dimension five-level (EQ-5D-5L) questionnaire, Clinical Frailty Scale (CFS), Basic Activity of Daily Living (BADL).
17. Questionnaires to address the respiratory impairment: Saint George Respiratory Questionnaire (SGRQ), Transition Dyspnoea Index (TDI), mMRC (Modified Medical Research Council) Dyspnea Scale
18. Questionnaires to address the mental health: Hospital Anxiety and Depression Scale (HADS), Kessler Psychologica
19. Perceived risk of re-infection on a scale 0-10 (no risk- very high risk); perceived risk of admission/re-admission on a scale 0-10 (no risk- very high risk)
20. Frequency mask-wearing (type of mask); frequency hand washing; respect of social distance; avoidance of social gathering
21. Was the vaccine accepted? Why not accepted (lack of trust in efficacy and/or safety; not useful in the specific case; prefer someone else gets it before me)
22. Cardiac MRI only if abnormal cardiac ultrasound
23. Blood tests: White blood cell count, lymphocyte count, neutrophil count, platelets, sodium, potassium, creatinine, glucose, bilirubin, alanine aminotransferase, aspartate aminotransferase, gamma glutamyl transpeptidase, albumin, lactate dehydrogenase, ferritin, creatine kinase, fibrinogen, INR, partial thromboplastin time, D-dimer, NT-pro-BNP, troponin, C-reactive protein (CRP), procalcitonin, venous lactate
24. Urine tests: pH, concentration, protein, glucose, red blood, white blood cell count
25. CD4 lymphocyte count; HIV-viral load; AIDS status
26. HIV-therapy: drug name and dose (only ongoing treatment); previous switch to other regimens for virological failure
27. Questionnaires to address cognitive status: Cognitive Failure Questionnaire (CFQ), Mini-Mental State Examination, Clinical Dementia rating Scale, Montreal Cognitive Assessment (MOCA).
28. Results of SARS-CoV-2 molecular test on amniotic fluid
29. Weight, height/length, cranial circumference, BMI
30. Type of transplant (heart, lung, kidney, liver, pancreas); single-combined; year of transplantation
31. Graft function: good, impaired, failure, rejection acute-chronic, recurrence of underlying disease, other
32. Immunosuppressive regimen: drug name and dose
33. According to Common Terminology Criteria for Adverse Events (CTCAE)
34. At least one of three timepoints (month 3, month 6, month 12) is required to perform metagenomics analysis.
35. At least one of the three timepoints (month 3, month 6, month 12) is required.